Press Release Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update Aug 12
Press Release Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 Aug 11